Development of New Hemostatic Dressings

新型止血敷料的研制

• 批准号: 7670536
• 负责人: Ruben Spretz
• 金额: $ 20万
• 依托单位: LNKCHEMSOLUTIONS
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-08-01 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7670536
• 关键词: Academic Medical Centers; Animal Model; Animal Testing; Animals; Back; Bandage; Behavior; Biochemistry; Biological; Biomedical Engineering; Blood; Blood Clot; Blood Coagulation Factor; Blood coagulation; Categories; Cattle; Classification; Coagulation Process; Collaborations; Development; Devices; Drug Formulations; Engineering; FDA approved; Family suidae; Fibrin Tissue Adhesive; Foundations; Generations; Goals; Hemorrhage; Hemostatic Agents; Hemostatic function; Human; In Vitro; Injury; International; Investigation; Kinetics; Lead; Letters; Marketing; Mechanics; Medical center; Military Personnel; Modeling; Nanostructures; Nanotechnology; Nebraska; Operative Surgical Procedures; Performance; Phase; Plants; Plasma; Pliability; Price; Process; Production; Property; Proteins; Recombinants; Red Cross; Research; Research Personnel; Resistance; Resources; Route; Running; Sampling; Scientist; Small Business Innovation Research Grant; Solutions; Staging; Sterile coverings; Structure; Surgeon; Temperature; Testing; Thrombelastography; Thrombin; Toxic effect; Universities; Vicryl; Work; Yeasts; animal data; base; biocompatible polymer; biomaterial compatibility; cost; design; experience; femoral artery; implantable device; improved; in vitro Model; in vitro testing; in vivo; multidisciplinary; nano; nanostructured; novel; poly(lactide); public health relevance; reconstitution; research and development; scaffold; stem; success; validation studies

DESCRIPTION (provided by applicant): A multidisciplinary team of researchers seeks to develop novel and economically feasible implantable hemostatic dressings for severe (e.g. arterial) bleeding. Key features of the device under development are its excellent pliability, biocompatibility, and nano/microengineered structure to maximize performance without requiring excessive amounts of procoagulants. LNKChemsolutions LLC and its academic partners will conduct in vitro (e.g., thromboelastography) and in vivo validation studies using a swine model, and focus initially on bandage formulations that are most likely to experience only modest to reasonable regulatory resistance. Long term goals focus on developing partnerships with national and international partners with animal, yeast and/or plant expression platforms for recombinant clotting factors. PUBLIC HEALTH RELEVANCE: This SBIR proposal is a multidisciplinary effort to develop new implantable dressings for hemorrhage control, with emphasis on treatment of severe arterial bleeding situations. Both the civilian and military markets will greatly benefit from important advances in the field.

描述（由申请人提供）：一个多学科的研究团队寻求开发新的和经济可行的植入式止血敷料严重（如动脉）出血。正在开发的设备的主要特点是其出色的柔韧性，生物相容性和纳米/微工程结构，以最大限度地提高性能，而不需要过量的促凝剂。LNKChemsolutions LLC及其学术合作伙伴将使用猪模型进行体外（例如，血栓弹性成像）和体内验证研究，并最初专注于最有可能只经历适度到合理的监管阻力的绷带配方。长期目标是与国内和国际合作伙伴建立合作伙伴关系，利用动物、酵母和/或植物表达平台重组凝血因子。公共卫生相关性：SBIR提案是一项多学科的努力，旨在开发用于出血控制的新型植入式敷料，重点是治疗严重动脉出血情况。民用和军用市场都将极大地受益于该领域的重要进展。